Spitler L E
Ann N Y Acad Sci. 1979;332:228-35. doi: 10.1111/j.1749-6632.1979.tb47116.x.
Results of therapeutic trials of transfer factor in a number of laboratories suggest clinical benefit and enhancement of immunological reactivity in patients with primary or secondary immunodeficiency diseases. Long term follow-up of 32 patients with the Wiskott-Aldrich syndrome suggested that transfer factor caused conversion of immunologic reactivity, apparent clinical benefit, and prolonged survival in some, but not in all patients. In 18 patients with disseminated (Stage III) malignant melanoma treated with surgery and transfer factor, survival was better than would ordinarily be expected for disseminated disease (78% with mean follow-up of 2 years). A randomized trial has been initiated which will answer the question of the efficacy of transfer factor as surgical adjuvant therapy in malignant melanoma. Studies in human subjects suggested that transfer factor does not cause enhancement of reactivity in normal subjects, when evaluated in a controlled, double-blind fashion. Similar controlled studies in immunodeficient patients are necessary to ascertain whether transfer factor does cause enhancement of immune responses in these patients. Based on these observations, a guinea pig model was developed in which transfer factor caused abrogation of tolerance to ABA-Tyrosine.
多个实验室对转移因子进行治疗试验的结果表明，其对原发性或继发性免疫缺陷疾病患者具有临床益处，并能增强免疫反应性。对32例维斯科特-奥尔德里奇综合征患者的长期随访表明，转移因子使部分（而非全部）患者的免疫反应性发生转变，有明显的临床益处，并延长了生存期。在18例接受手术和转移因子治疗的播散性（III期）恶性黑色素瘤患者中，生存期比播散性疾病通常预期的要好（平均随访2年，生存率为78%）。一项随机试验已经启动，它将回答转移因子作为恶性黑色素瘤手术辅助治疗的疗效问题。在人体受试者中进行的研究表明，以对照、双盲方式评估时，转移因子不会增强正常受试者的反应性。对免疫缺陷患者进行类似的对照研究对于确定转移因子是否确实能增强这些患者的免疫反应是必要的。基于这些观察结果，建立了一种豚鼠模型，在该模型中转移因子可消除对ABA-酪氨酸的耐受性。
